Table 1 Characteristics and survivals of the study’ patients ablated for naive HCC.
Variables | n = 1571 |
|---|---|
Age [years; median (IQR)] | 62 (54–70) |
<60 years | 670 (42.6%) |
60–70 years | 538 (34.2%) |
71–80 years | 305 (19.4%) |
>80 years | 58 (3.7%) |
Male gender | 1197 (76.2%) |
Eastern patients | 886 (56.4%) |
Year of ablation | |
2004–2008 | 166 (10.6%) |
2009–2013 | 524 (33.3%) |
2014–2018 | 881 (56.1%) |
Etiology | |
Hepatitis B | 774 (49.5%) |
Hepatitis C | 359 (22.9%) |
Alcohol | 235 (15.0%) |
Other | 253 (16.1%) |
Total bilirubin [μmol/L; median (IQR)] | 16.0 (11.0–23.8) |
Serum albumin [g/L; median (IQR)] | 40 (36–44) |
ALBI grade | |
1 | 592 (37.7%) |
2 | 866 (55.2%) |
3 | 111 (7.1%) |
MWA | 217 (13.8%) |
Largest tumour size [cm; median (IQR)] | 2.5 (1.9–3.4) |
Tumour number | |
Single | 1176 (74.9%) |
2 or 3 nodules | 340 (21.6%) |
4+ nodules | 55 (3.5%) |
BCLC very-early stage | 317 (20.2%) |
Milan IN | 1358 (86.4%) |
Disease-free survival [years; median (IQR)] | 1.3 (0.5–3.6) |
1 year (95% C.I.) | 58.5% (55.9–60.9) |
3 years (95% C.I.) | 30.4% (27.9–32.9) |
5 years (95% C.I.) | 19.1% (16.4–21.4) |
10 years (95% C.I.) | 8.8% (6.1–12.3) |
Overall survival [years; median (IQR)] | 5.0 (2.2–9.6) |
1 year (95% C.I.) | 90.2% (88.5–91.6) |
3 years (95% C.I.) | 67.5% (64.8–70.2) |
5 years (95% C.I.) | 49.9% (46.6–53.2) |
10 years (95% C.I.) | 20.8% (16.0–26.1) |
